A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia

Upadya, Haridas; Prabhu, S.; Prasad, Aravinda; Subramanian, Deepa; Gupta, Swati; Goel, Ajay

doi:10.1186/s12906-019-2430-y

BMC Complementary Medicine and Therapies

Table 2 Table with p values within the group (amla extract/placebo) and between groups

From: A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia

Triglycerides (mg/dl)
	Placebo		Amla extract		Between groups (MW)
	Initial	Final	Initial	Final	Initial	Final
Mean TG levels (mg/dl)	247.617	210.469	261.106	171.939
p (within group) (W)	p = 0.0007		p < 0.0001		p = 0.8367	p = 0.0003
Decrease in TG (n)	35		44
Increase in TG (n)	14		4
No change (n)	0		1
p (chi-square)	p = 0.021
Total Cholesterol (mg/dl)
	Placebo		Amla extract		Between groups (MW)
	Initial	Final	Initial	Final	Initial	Final
Mean TC levels (mg/dl)	225.735	212.551	231.673	177
p (within group) (W)	p = 0.0098		p < 0.0001		p = 0.2707	p = 0.0003
Decrease in TC (n)	31		40
Increase in TC (n)	16		9
No change	2		0
p (chi-square)	P = 0.129
Low Density Lipoproteins (mg/dl)
	Placebo		Amla extract		Between groups (MW)
	Initial	Final	Initial	Final	Initial	Final
Mean LDL levels (mg/dl)	132.155	126.059	139.963	111.531
p (within group) (W)	p = 0.1008		p < 0.0001		p = 0.0404	p = 0.0064
Decrease in LDL (n)	28		36
Increase in LDL (n)	20		13
No change (n)	1		0
p (chi-square)	P = 0.174
High Density Lipoproteins (mg/dl)
	Placebo		Amla extract		Between groups (MW)
	Initial	Final	Initial	Final	Initial	Final
Mean HDL levels (mg/dl)	43.418	41.659	43.657	39.339
p (within group) (W)	p = 0.2849		p = 0.0002		p = 0.5527	p = 0.0149
Decrease in HDL (n)	28		36
Increase in HDL (n)	21		12
No change (n)	0		1
p (chi-square)	p = 0.101
Atherogenic Index of Plasma
	Placebo		Amla extract		Between groups
	Initial	Final	Initial	Final	Initial (MW)	Final (T-test)
Mean AIP level	0.410	0.347	0.426	0.261
p (within group) (W)	p = 0.0098		p < 0.0001		p = 0.8119	p = 0.0177
Decrease in AIP (n)	31		40
Increase in AIP (n)	18		8
No change (n)	0		1
p (chi-Square)	p = 0.045
CoQ10 (ng/ml)
	Placebo		Amla extract		Between groups
	Initial	Final	Initial	Final	Initial (MW)	Final (T-test)
Mean CoQ10 levels (ng/ml)	48.691	49.602	47.146	45.975
p (within group)	p = 0.6744 (t-test)		p = 0.2942 (W)		p = 0.7788	p = 0.4581
Decrease in CoQ10 (n)	14		18
Increase in CoQ10 (n)	16		12
No change (n)	0		0
p (chi-Square)	p = 0.438
Ratio of Apo B/Apo A1
	Placebo		Amla extract		Between groups (MW)
	Initial	Final	Initial	Final	Initial	Final
Mean value	0.869	0.853	1.004	0.948
p (within group)	p = 0.6434 (t-test)		p = 0.0419 (W)		p = 0.0528	p = 0.0866
Decrease in Apo B/Apo A1 ratio (n)	27		31
Increase in Apo B/Apo A1 ratio (n)	21		18
No change (n)	0		0
p (chi-Square)	p = 0.619

T-test Independent t-test, t-test Paired t test, MW Mann whitney test, W Wilcoxon signed rank test. No change Not included in the calculation

Back to article page

ISSN: 2662-7671

Contact us

Submission enquiries: bmccomplementarymedicineandtherapies@biomedcentral.com
General enquiries: ORSupport@springernature.com